OCEAN(a) Outcomes
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
- Stage
- followup
- Medicine
- Olpasiran
- Population
- ASCVD
- Phase
- III
- First Patient In
- 12 May 2023
- Last Patient In
- 31 January 2024
- Last Patient Last Visit
- 1 January 2028
National Lead
prof. dr. J. W. Jukema
Cardioloog
Study Director
dr. J. Schaap
Cardioloog
Office Contact
